Biogen Inc. (BIIB)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Multiple Sclerosis Product Revenue	4.04B	4.04B	4.35B
Multiple Sclerosis Product Revenue Growth	0.11%	-7.15%	-6.69%
Rare Disease Product Revenue	2.15B	2.15B	1.99B
Rare Disease Product Revenue Growth	-0.28%	8.36%	10.27%
Biosimilars Product Revenue	730.50M	729.10M	793.10M
Biosimilars Product Revenue Growth	0.19%	-8.07%	3.00%
Other Product Revenue	223.20M	197.20M	82.50M
Other Product Revenue Growth	13.18%	139.03%	599.15%
Revenue (Other)	2.79B	2.77B	2.46B
Revenue (Total)	9.94B	9.89B	9.68B
Revenue (Total) Growth	0.47%	2.22%	-1.62%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	3.63B	3.55B	3.24B
United States Revenue Growth	2.41%	9.59%	3.05%
Rest of World Revenue	3.51B	3.57B	3.98B
Rest of World Revenue Growth	-1.67%	-10.18%	-3.15%
Revenue (Other)	2.79B	2.77B	2.46B
Revenue (Total)	9.94B	9.89B	9.68B
Revenue (Total) Growth	0.47%	2.22%	-1.62%

Updated Apr 29, 2026. Data Source: Fiscal.ai.